Roche Holding (RHHBY)
(Delayed Data from OTC)
$40.71 USD
-0.01 (-0.02%)
Updated Aug 2, 2024 04:00 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RHHBY 40.71 -0.01(-0.02%)
Will RHHBY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RHHBY
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
Other News for RHHBY
Regeneron price target raised to $805 from $720 at BofA
REGENXBIO releases new data on DMD drug ahead of earnings
Roche price target raised by CHF 10 at JPMorgan
Roche's Vabysmo gains indication in Europe for retinal vein occlusion
Truist healthcare analyst holds an analyst/industry conference call